

# Philip Eg Aylward

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4961522/publications.pdf>

Version: 2024-02-01

7  
papers

173  
citations

1683934  
5  
h-index

1872570  
6  
g-index

7  
all docs

7  
docs citations

7  
times ranked

268  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020, 41, 4245-4255.	1.0	117
2	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014, 168, 68-75.e2.	1.2	18
3	Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox. <i>Clinical Cardiology</i> , 2019, 42, 1028-1040.	0.7	14
4	Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2022, 145, 1581-1591.	1.6	13
5	Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: Practical perspectives based on data from the TREAT study. <i>Clinical Cardiology</i> , 2018, 41, 1322-1327.	0.7	6
6	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE-TIMI 60 trial. <i>American Heart Journal</i> , 2022, 243, 147-157.	1.2	5
7	Abstract 16820: Albuminuria and Outcomes in Patients With Non-ST-segment Elevation Acute Coronary Syndromes: Results From the TRACER Trial. <i>Circulation</i> , 2015, 132, .	1.6	0